14 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of esketamine hydrochloride in the NHS in England.

Esketamine hydrochloride, when used in combination with a selective serotonin re-uptake inhibitor or a serotonin norepinephrine re-uptake inhibitor, is not recommended for adults with treatment-resistant depression that has not responded to at least two different anti-depressants in the current moderate to severe depressive episode.

Read NICE technology appraisal guidance